StocksD › DMAC

DiaMedica Therapeutics Inc. (DMAC) — Earnings Call X-Ray

Our AI read all 25 of DMAC's earnings calls (2019–2025) and answered the same battery of questions about each one. Every past call is free; the newest quarter unlocks with a free account.

Latest Call Grade
🔒
Q1 2025 · sign up to see
Previous Call Grade
D
Q4 2024
Expected Move
🔒
next 45 days · members
Calls Analyzed
25
2019–2025
Avg Candor
6.7/9
evasion 2.5/9
Guidance LoweredHigh CandorCritic AmmunitionDemand AcceleratingCapex IncreasingReads RehearsedQuestion Left HangingResults Worse Than Direction

Call-by-call analysis

🔒 Q1 2025 earnings call 2025-05-14 NEWEST

Guidance: ■■■■■Demand: ■■■■■■ Margins: ■■■■Backlog: ■■■■ ■ analysts, ■■ questionsexpected move ±■■%
Candor /9
Specificity /9
Evasion /9
Stress /9

Management ■■■■■■ guidance against ■■■■■■■■ demand and ■■■■■■■ margins. The delivery was ■■■■■■■■ and ■■■■ in specifics, with ■■■ questions left hanging.

🔒 The Q1 2025 call grade is ready
The full 37-point AI read of DMAC's newest earnings call — grade, expected move, and every question answered — is free with an account.
Sign up free to unlock

D Q4 2024 earnings call 2025-03-18 move ±11.9%

Management lowered guidance against accelerating demand. The delivery was unusually candid, rich in specifics.

Guidance: loweredDemand: acceleratingHeadcount: growingCapex: increasing 4 analysts · 9 questions
⚑ Critic ammunition⚑ Question left hanging✓ Resolves doubts⚑ Reads rehearsedDirection beats results
Candor 7/9
Specificity 7/9
Evasion 3/9
Confidence 7/9
Uncertainty 4/9
Promotion 6/9
Stress 2/9
Complexity 6/9
All 20 questions our AI answered about this call
NO Would a skeptical short-seller find this call reassuring?
NO Would a careful investor underwrite management's guidance?
YES Is management's confidence proportionate to the evidence presented?
YES Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
YES Does an obvious question remain unanswered?
NO Is a product early in its life but growing very fast?
NO Do they serve a small fraction of their addressable customers?
NO Is volume about to step up rather than grow gradually?
NO Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
YES Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
NO Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
YES Does the call read rehearsed rather than lived?

D Q3 2024 earnings call 2024-11-14 move ±10%

Management lowered guidance against contracting margins. The delivery was unusually candid, rich in specifics.

Guidance: loweredMargins: contractingHeadcount: growingCapex: increasing 4 analysts · 11 questions
⚑ Critic ammunition✓ Resolves doubts✓ Volume step-up ahead⚑ Reads rehearsedDirection beats results
Candor 7/9
Specificity 8/9
Evasion 2/9
Confidence 8/9
Uncertainty 3/9
Promotion 6/9
Stress 3/9
Complexity 7/9
All 20 questions our AI answered about this call
NO Would a skeptical short-seller find this call reassuring?
NO Would a careful investor underwrite management's guidance?
NO Is management's confidence proportionate to the evidence presented?
YES Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
NO Does an obvious question remain unanswered?
NO Is a product early in its life but growing very fast?
YES Do they serve a small fraction of their addressable customers?
YES Is volume about to step up rather than grow gradually?
NO Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
YES Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
NO Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
YES Does the call read rehearsed rather than lived?

C+ Q2 2024 earnings call 2024-08-11 move ±12.4%

Management gave no formal guidance against accelerating demand. The delivery was unusually candid, rich in specifics.

Demand: acceleratingHeadcount: growing 2 analysts · 3 questions
⚑ Critic ammunition⚑ Question left hanging✓ Resolves doubts✓ Volume step-up ahead⚑ Reads rehearsed
Candor 7/9
Specificity 8/9
Evasion 1/9
Confidence 7/9
Uncertainty 3/9
Promotion 6/9
Stress 2/9
Complexity 5/9
All 20 questions our AI answered about this call
NO Would a skeptical short-seller find this call reassuring?
NO Would a careful investor underwrite management's guidance?
YES Is management's confidence proportionate to the evidence presented?
YES Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
YES Does an obvious question remain unanswered?
NO Is a product early in its life but growing very fast?
YES Do they serve a small fraction of their addressable customers?
YES Is volume about to step up rather than grow gradually?
NO Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
NO Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
NO Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
YES Does the call read rehearsed rather than lived?

D Q1 2024 earnings call 2024-05-11 move ±16%

Management held guidance steady against accelerating demand. The delivery was unusually candid.

Guidance: maintainedDemand: acceleratingHeadcount: growing 3 analysts · 9 questions
⚑ Critic ammunition⚑ Question left hanging✓ Volume step-up ahead⚑ Reads rehearsedDirection beats results
Candor 7/9
Specificity 6/9
Evasion 3/9
Confidence 7/9
Uncertainty 5/9
Promotion 6/9
Stress 2/9
Complexity 4/9
All 20 questions our AI answered about this call
NO Would a skeptical short-seller find this call reassuring?
NO Would a careful investor underwrite management's guidance?
YES Is management's confidence proportionate to the evidence presented?
NO Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
YES Does an obvious question remain unanswered?
NO Is a product early in its life but growing very fast?
YES Do they serve a small fraction of their addressable customers?
YES Is volume about to step up rather than grow gradually?
NO Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
YES Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
NO Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
YES Does the call read rehearsed rather than lived?

D Q4 2023 earnings call 2024-03-20 move ±11.2%

Management gave no formal guidance. The delivery was rich in specifics.

Headcount: growing 3 analysts · 8 questions
⚑ Critic ammunition⚑ Question left hanging✓ Volume step-up ahead⚑ Reads rehearsedDirection beats results
Candor 6/9
Specificity 7/9
Evasion 3/9
Confidence 7/9
Uncertainty 4/9
Promotion 5/9
Stress 3/9
Complexity 6/9
All 20 questions our AI answered about this call
NO Would a skeptical short-seller find this call reassuring?
NO Would a careful investor underwrite management's guidance?
YES Is management's confidence proportionate to the evidence presented?
NO Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
YES Does an obvious question remain unanswered?
NO Is a product early in its life but growing very fast?
NO Do they serve a small fraction of their addressable customers?
YES Is volume about to step up rather than grow gradually?
NO Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
YES Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
NO Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
YES Does the call read rehearsed rather than lived?

C Q3 2023 earnings call 2023-11-14 move ±12.4%

Management gave no formal guidance against contracting margins. The delivery was unusually candid, rich in specifics.

Margins: contractingHeadcount: growing 3 analysts · 10 questions
⚑ Critic ammunition⚑ Question left hanging⚑ Reads rehearsedDirection beats results
Candor 7/9
Specificity 8/9
Evasion 2/9
Confidence 6/9
Uncertainty 4/9
Promotion 5/9
Stress 2/9
Complexity 8/9
All 20 questions our AI answered about this call
NO Would a skeptical short-seller find this call reassuring?
NO Would a careful investor underwrite management's guidance?
YES Is management's confidence proportionate to the evidence presented?
NO Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
YES Does an obvious question remain unanswered?
NO Is a product early in its life but growing very fast?
NO Do they serve a small fraction of their addressable customers?
NO Is volume about to step up rather than grow gradually?
NO Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
YES Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
NO Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
YES Does the call read rehearsed rather than lived?

C+ Q2 2023 earnings call 2023-08-15 move ±15.2%

Management gave no formal guidance. The delivery was unusually candid, rich in specifics.

Headcount: growing 3 analysts · 10 questions
⚑ Critic ammunition⚑ Question left hanging✓ Resolves doubts⚑ Reads rehearsed
Candor 7/9
Specificity 8/9
Evasion 2/9
Confidence 7/9
Uncertainty 5/9
Promotion 6/9
Stress 2/9
Complexity 6/9
All 20 questions our AI answered about this call
NO Would a skeptical short-seller find this call reassuring?
NO Would a careful investor underwrite management's guidance?
YES Is management's confidence proportionate to the evidence presented?
YES Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
YES Does an obvious question remain unanswered?
NO Is a product early in its life but growing very fast?
NO Do they serve a small fraction of their addressable customers?
NO Is volume about to step up rather than grow gradually?
NO Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
NO Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
NO Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
YES Does the call read rehearsed rather than lived?

Earlier calls

CallDateGradeGuidanceDemandMarginsCandorEvasion
Q1 2023 2023-05-16 C noneunclearcontracting 7/9 2/9
Q4 2022 2023-03-29 C noneunclearcontracting 7/9 2/9
Q2 2022 2022-08-11 C noneunclearcontracting 7/9 3/9
Q1 2022 2022-05-06 C maintainedunclearunclear 7/9 2/9
Q4 2021 2022-03-15 D noneunclearcontracting 6/9 4/9
Q3 2021 2021-11-11 D noneunclearcontracting 7/9 3/9
Q2 2021 2021-08-12 D noneunclearunclear 6/9 3/9
Q1 2021 2021-05-09 C maintainedunclearcontracting 6/9 3/9
Q4 2020 2021-03-11 D noneunclearcontracting 6/9 3/9
Q3 2020 2020-11-08 C noneunclearunclear 8/9 2/9
Q2 2020 2020-08-12 D noneslowingunclear 7/9 2/9
Q1 2020 2020-05-14 F withdrawnunclearunclear 6/9 2/9
Q4 2019 2020-03-24 F withdrawnslowingunclear 7/9 4/9
Q3 2019 2019-11-14 D maintainedunclearunclear 6/9 2/9
Q2 2019 2019-08-14 B noneunclearcontracting 7/9 2/9
Q1 2019 2019-05-14 C+ maintainedunclearcontracting 7/9 1/9
Q4 2018 2019-03-20 D noneunclearcontracting 6/9 4/9

How to read this page

The grade is a transparent composite of call quality — candor, specificity, low evasion, low stress, whether the call resolves more doubts than it creates, and the guidance action — not a buy or sell signal. The expected move is a volatility estimate from the one signal that survived our out-of-sample tests: how a stock's own reaction and pre-call volatility predict the size (not direction) of its next move. Full detail, including everything that failed: methodology.

Companies with similar call quality

AAC · AAC Holdings'AACAY · AAC Technologies HoldingAACG · ATA Creativity GlobalAADI · Aadi Bioscience, Inc.AALBF · Aalberts N.V.AAOI · Applied Optoelectronics,

DM   All “D” companies    DMCAF

Not investment advice. Artul.ai publishes AI-generated earnings-call quality grades and expected-volatility estimates — never buy or sell recommendations. We tested over 1,600 predictive hypotheses against 165,000 transcripts; the honest result, including what failed, is documented in our methodology.